Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06279-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Tom Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: GSK plc, Philadelphia, PA, USA. tom.x.liu@gsk.com. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles, Anemia, Patient Acceptance of Health Care. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GSK plc.
Abstract (Originalsprache)
Anemia affects many patients with myelofibrosis and is associated with poor prognosis. The Janus kinase inhibitor ruxolitinib is often used in myelofibrosis but may cause or worsen anemia. Using healthcare claims data from the IQVIA PharMetrics Plus database, this retrospective analysis evaluated healthcare resource utilization (HCRU), healthcare costs, and treatment patterns in ruxolitinib-treated patients with myelofibrosis stratified by anemia diagnosis prior to ruxolitinib initiation. Of 11,499 patients diagnosed with myelofibrosis between January 2011 and December 2022, 481 had ≥ 1 ruxolitinib claim on or after the myelofibrosis diagnosis date and were included in this analysis. Mean follow-up was 2.0 years. At baseline, anemic patients (n = 257) were older (mean age, 60.2 vs. 56.8 years; P < 0.001) and had a higher mean Charlson Comorbidity Index (1.0 vs. 0.5; P < 0.001) than nonanemic patients (n = 224). During follow-up, anemic patients exhibited higher median annual all-cause HCRU (inpatient admissions, 0.3 vs. 0.0 [P < 0.001]; outpatient visits, 40.0 vs. 20.0 [P < 0.001]; emergency department visits, 0.4 vs. 0.0 [P < 0.010]) and also had numerically higher median annual all-cause total healthcare costs ($198,491 vs. $170,419; P = 0.549) and medical costs ($44,830 vs. $12,017; P = 0.638) but significantly lower median annual total pharmacy costs ($129,381 vs. $136,686; P < 0.050), compared with nonanemic patients. Ruxolitinib discontinuation rates were higher and median time to discontinuation was approximately 1 year earlier in anemic patients (14.1 vs. 23.8 months; P < 0.010). In conclusion, patients with myelofibrosis and baseline anemia who are treated with ruxolitinib may be an HCRU-intensive population, suggesting a potential need for alternative treatments that reduce their medical resource burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK plc, Philadelphia, PA, USA. tom.x.liu@gsk.com.
- Analysis Group, Boston, MA, USA.
- GSK plc, Philadelphia, PA, USA.
ORCID-Profile: Mirko Fillbrunn, Shiyuan Zhang, Jingyi Chen, Nicole Niehoff, Gautam Sajeev, James Signorovitch
Förderung
- GSK plc
Zitieren
APA
Liu, T., Fillbrunn, M., Zhang, S., Chen, J., Li, W., Platt, J., Niehoff, N., Sajeev, G., & Signorovitch, J. (2025). Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis. Annals of Hematology. https://doi.org/10.1007/s00277-025-06279-0
Vancouver
Liu T, Fillbrunn M, Zhang S, Chen J, Li W, Platt J, et al. Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis. Annals of Hematology. 2025. doi:10.1007/s00277-025-06279-0
BibTeX
@article{Liu2025,
author = {Liu, Tom and Fillbrunn, Mirko and Zhang, Shiyuan and Chen, Jingyi and Li, Weilong and Platt, Julia and Niehoff, Nicole and Sajeev, Gautam and Signorovitch, James},
title = {Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06279-0}
}
EUVIMED